Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare Biotechnology

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc

Bullboard Posts

Comment by Stylesson Mar 26, 2015 12:11pm

43 Views

Post# 23564575

RE:RE:Well for those of you who don't like truth put me on ignore

There's only one truth here. The share price performance drop is dramatic and alarming.

You can't deny what the market has done. and it's clearly turning bearish on CPH. That's just a fact. Not really up for interpretation. Doesn't help that analysts continue to have hold rating on the stock even with it's 50% plunge.

Bullboard Posts

Global Tungsten Market and Supply Security